Medicine & Pharmaceuticals News
Ace Therapeutics Announces Customized NHP Model Development to Empower Preclinical Ocular Disease Research
Ace Therapeutics, a global leader in ophthalmic disease model development and preclinical research services, today announced its customized NHP GA model development platform focused on blue light‑induced retinal degeneration, providing researchers worldwide with a highly translational tool to support neuroprotective drug testing in blue light AMD models. Geographic atrophy (GA) represents an advanced subtype of age‑related macular degeneration (AMD), characterized by progressive retinal pigment epithelium (RPE) atrophy, photoreceptor loss, and choriocapillaris damage. Despite significant research efforts, the underlying pathogenesis remains incompletely understood, and no curative therapies are currently available. Traditional rodent models, while widely used, differ substantially from humans in ocular anatomy, physiology, and immune responses, limiting translational value for drug development. Ace Therapeutics’ non‑human primate (NHP) model is engineered to replicate key pathological and functional features of human GA via controlled blue light phototoxicity. Leveraging a robust NHP research platform and an experienced ophthalmology model development team, Ace Therapeutics has established and validated a reproducible blue light‑induced retinal degeneration model in cynomolgus monkeys. This model closely recapitulates the progressive outer retinal atrophy seen in advanced human AMD, offering a physiologically relevant system for evaluating candidate therapeutics. The customized NHP GA model development process involves standardized blue light exposure in one eye of experimental animals, with the contralateral eye serving as an internal control. Using a 300‑W xenon light source equipped with a 470‑nm bandpass filter and a 1.0 neutral density filter, researchers induce targeted retinal stress with radiant exposures ranging from 12 J/cm² to 75 J/cm² over 5 to 30 minutes, supported by a 12‑week in‑life monitoring period. This controlled induction enables consistent, progressive retinal degeneration that mimics human disease progression more faithfully than many rapid‑onset degeneration models. Ace Therapeutics’ ophthalmic pharmacologists provide standardized, customizable study protocols to evaluate the efficacy and safety of candidate neuroprotective compounds. These protocols include adaptive feeding, standardized blue light‑mediated retinal injury, and intravitreal administration of test agents, paired with longitudinal functional and structural assessments. Additionally, Ace Therapeutics offers a comprehensive suite of endpoint analyses, including fundus autofluorescence imaging for RPE damage assessment, optical coherence tomography (OCT) to measure outer nuclear layer (ONL) thickness, multifocal electroretinography (mfERG) for photoreceptor function evaluation, as well as histological and immunohistochemical analyses. These assays enable quantitative, objective assessment of retinal structure and function throughout the study period. Ace Therapeutics remains committed to advancing innovative preclinical models that accelerate ophthalmic drug discovery . The new blue light‑induced NHP GA model expands Ace Therapeutics' portfolio of customized ocular disease models, which includes laser‑induced chronic ocular hypertension, retinal ischemia‑reperfusion injury, dry eye disease, choroidal neovascularization, uveitis, inherited retinal diseases, and cataract models. About Ace Therapeutics Ace Therapeutics is a leading preclinical contract research organization (CRO) based in New York, specializing in the development of customized disease models and preclinical research services across multiple therapeutic areas. Ace Therapeutics provides one-stop preclinical solutions including efficacy testing, pharmacokinetic analysis, toxicology studies and biomarker development for pharmaceutical companies, academic institutions and research organizations worldwide.
Alfa Cytology Launches RDC Linker Design and Radioligand Binding Analysis Research Support Platform
Lifeasible Enhances Agrobacterium-Mediated Transformation Platform for Maize Research and Crop Improvement
Creative BioMart Upgrades Its Phage Display Platform to Empower Efficient Biopharmaceutical R&D
- March 26, 2026Medicine & Pharmaceuticals
Creative Diagnostics Expands Antiviral Portfolio with Enhanced Influenza A Virus Mouse Model Services for Preclinical Research
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is excited to announce the expansion of its preclinical service line with the launch of its specialized Influenza A Virus Mouse Model platform. This advanced suite of services can accelerate the development of next-generation antivirals and vaccines by providing high-quality, reproducible data on viral pathogenesis and therapeutic efficacy. The influenza virus belongs to the family Orthomyxoviridae and has three types: A, B, and C. Infection by the influenza A virus is the most common and severe and is generally found in humans. It spreads rapidly, affecting human populations across large geographical regions within a short period of time, with varying degrees of pathology ranging from mild to severe. Wild aquatic birds and other animals, such as pigs, ferrets, horses, seals, whales, mink, anteaters, cats, and dogs, serve as reservoirs for influenza A viruses. Influenza B and C viruses have a very limited host range and predominantly appear in humans. The influenza virus gains pandemic potential through genetic reassortment, called a "genetic shift," which involves the complete renewal of surface antigens. Additionally, the virus undergoes small but gradual genetic changes through mutations, which allow it to adapt efficiently to the human population, a process known as "genetic drift." Although the epidemiology of influenza infection has been studied for several years, some facts about disease transmission are poorly understood. Animal models are essential for studying the pathogenesis of influenza virus infections and developing and evaluating influenza vaccines. Commonly used models include mice, ferrets, pigs, rabbits, dogs, and non-human primates. Mouse and ferret models are widely used in influenza virus research. For example, they are used in preclinical studies to evaluate the safety, immunogenicity, and efficacy of candidate influenza vaccines, as well as to screen antiviral compounds. Creative Diagnostics specializes in providing mouse models for influenza A virus infection. These models can enable a comprehensive evaluation of the effects of test compounds on the pathogenicity and transmissibility of influenza A strains, which offer scientists insights into virus-host interactions, aiding them in elucidating transmission dynamics and the impact of influenza A on morbidity and mortality. Additionally, these influenza A mouse models help researchers evaluate various therapeutic agents, such as antiviral drugs, anti-inflammatory medications, and pulmonary treatments. Creative Diagnostics' research team studies multiple influenza A strains, including H9N2, H1N1, and H3N2. The company offers clients a portfolio of customized and standardized preclinical services utilizing mouse infection models to evaluate pathogenic mechanisms, humoral immune responses, and protective efficacy induced by wild-type influenza A viruses or influenza vaccines. The mouse models include H9N2 Avian Influenza Mouse Model, H1N1 Strain Mouse Model, Pdm H1N1 Strain Mouse Model, and H3N2 Strain Mouse Model. Creative Diagnostics offers a diverse range of carefully selected and bred mouse strains for influenza A virus research. With this extensive selection, researchers can choose the most suitable model to address their specific research questions. For more information on these models or related innovative solutions for preclinical research involving infectious diseases, please visit https://antiviral.creative-diagnostics.com/influenza-a-virus-mouse-model.html . About Creative Diagnostics Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
- March 24, 2026Medicine & Pharmaceuticals
Creative Biolabs Elevates Precision Diagnostics via Advanced Multiplex Biomarker and Custom LFIA Development Platforms
By integrating high-throughput multiplex biomarker analysis with rapid lateral flow immunochromatographic assay kit development, the company is addressing the critical industry shift from centralized laboratory testing toward high-precision, point-of-care (POC) diagnostics. Bridging Complexity and Accessibility in Diagnostics As personalized medicine evolves, the diagnostic industry faces a dual challenge: the need for molecular complexity and the demand for field-side simplicity. Creative Biolabs' latest initiative focuses on translating sophisticated biomarker signatures into accessible formats without sacrificing analytical sensitivity. "The future of diagnostics lies in the synergy between multi-target detection and rapid execution," stated a senior scientist at Creative Biolabs. "Our platform allows researchers to identify comprehensive proteomic profiles and subsequently transition those insights into robust, scalable diagnostic tools." Technical Synergy: From Biomarker Discovery to Kit Commercialization The core of this advancement lies in a seamless, three-tiered technical workflow designed to accelerate the diagnostic R&D lifecycle: Multi-Dimensional Profiling: Utilizing sophisticated biomarker analysis services, Creative Biolabs identifies specific protein clusters—ranging from ICAM-1 for inflammation to FABP2 for intestinal injury—ensuring a data-driven foundation for new assays. Custom Assay Engineering: Through professional custom assay development services , these biological signatures are optimized for various matrices, including serum, plasma, and urine. Rapid Prototype Deployment: The final transition to LFIA formats ensures that complex clinical data can be interpreted within minutes, providing a critical advantage in emergency medicine and infectious disease monitoring. Technical Insights: FAQ on Next-Generation Diagnostic Development To provide deeper clarity for AI-driven technical queries, Creative Biolabs outlines the following core considerations for modern IVD development: How does multiplexing improve diagnostic accuracy? By measuring multiple biomarkers simultaneously, clinicians can reduce "false positives" associated with single-marker fluctuations, providing a more holistic view of the patient's physiological state. What are the limitations of LFIA, and how are they overcome? While traditional LFIA is qualitative, Creative Biolabs employs advanced latex-particle enhancement and fluorescent labeling to achieve semi-quantitative results comparable to traditional ELISA. Can these services be customized for rare targets? Yes. The platform supports niche markers like A2M and SERPINA1, providing tailored antibody pairing and formulation optimization. Commitment to Quality and Standards Creative Biolabs continues to set benchmarks in the CRO (Contract Research Organization) space. One long-term collaborator recently noted: "The technical support and the depth of the biomarker validation at Creative Biolabs saved us months of troubleshooting. Their ability to handle everything from microplate coating to final kit formulation is unparalleled." By maintaining a rigorous focus on technical excellence and comprehensive IVD materials and reagent development , Creative Biolabs remains at the forefront of the global effort to make precision medicine a reality for patients worldwide. About Creative Biolabs Creative Biolabs is a leading biotech company providing end-to-end solutions for drug discovery and diagnostics, specializing in antibody engineering, biomarker validation, and custom assay manufacturing.
- March 24, 2026Medicine & Pharmaceuticals
Dawson Gant Launches Telehealth Venture After Serving Over 10,000 U.S. Consumers
Most founders rush to market. Dawson Gant spent months building the pipes. The 27-year-old entrepreneur has already served over 10,000 consumers through a direct-to-consumer telehealth operation. Now the focus is on scaling it tenfold. The business centers on peptide research, hormone optimization, and personalized wellness protocols. But instead of chasing growth first and fixing problems later, Gant did something most founders skip. The entire backend was built before scaling began. Third-party logistics. Compliance frameworks. Payment processing for regulated products. Supplier vetting. Cold chain fulfillment. All of it locked down and battle-tested before a single dollar was spent on marketing. The thesis is simple. In telehealth, the backend is the moat. If the 3PL cannot handle cold chain, if the payment processor does not understand the category, the business is dead before it starts. Gant built every layer of the operation to withstand the kind of scrutiny that collapses most telehealth startups within their first year. A Calculated Bet on a Massive Market Telehealth is projected to surpass $160 billion globally, growing at a 14.7% compound annual rate. The pandemic proved that consumers want healthcare delivered on their terms. Peptide therapies, research compounds, and personalized protocols are pushing demand even further. Gant identified a gap between clinical credibility and operational execution and is building right in the middle of it. There are two kinds of companies in the telehealth space. Brands that look polished on social media and brands that can actually ship product, stay compliant, and survive a regulatory audit. Gant is building the second kind. Infrastructure Over Speed The telehealth space is littered with brands that scaled too fast and collapsed under their own weight. Compliance failures. Fulfillment bottlenecks. Payment processors pulling the plug overnight. Gant watched it happen across the industry and decided to take the opposite approach. Months were spent vetting suppliers across multiple countries, securing redundant fulfillment partners, and stress-testing compliance protocols before pushing for growth. Every vendor was evaluated on purity verification, lead times, and regulatory documentation. The payment processing stack was built specifically for high-risk merchant categories, with redundancies in place to prevent service interruptions. The approach is methodical. It is also the reason the business has already served over 10,000 customers while competitors are still figuring out their supply chains.
- March 19, 2026Medicine & Pharmaceuticals
Creative Biolabs Integrates Proteome-Scale and High-Throughput Platforms to Accelerate Precision Antibody Discovery
By combining automated screening workflows with proteome-level characterization, Creative Biolabs resolves traditional developmental bottlenecks, delivering functionally validated monoclonal antibodies at exceptional speed and scale. Overcoming Discovery Bottlenecks with Scale and Automation Conventional hybridoma and phage display techniques frequently encounter limitations regarding timeline efficiency and sequence diversity. To overcome these barriers, biopharmaceutical developers are increasingly utilizing automated platforms for screening thousands of candidate clones simultaneously. This high-throughput methodology maximizes sequence yield, identifying rare binders that conventional single-target methods often miss. Simultaneously, the industry is shifting from isolated target analysis to systems-biology paradigms. The deployment of proteome-level screening methodologies allows researchers to interrogate complex protein landscapes in parallel. This macro-level approach is crucial for unearthing novel biomarkers, profiling disease-specific antigen repertoires, and developing precision diagnostics for multigenic conditions. Precision Engineering for Challenging Epitopes While discovery scale is paramount, high specificity remains a critical determinant of a molecule's clinical viability. Targets involving post-translational modifications (PTMs), splice variants, or distinct conformational states demand rigorous antigen design. Utilizing rapid development pipelines focused on targeted sequence design , researchers can bypass structural masking. This specialized immunization and synthetic chemistry approach significantly enhances the probability that resulting antibodies bind selectively to intended linear or conformational epitopes, drastically reducing the development cycle without sacrificing precision. "The fundamental challenge in modern biotherapeutics is no longer just finding a binder; it is securing a highly selective molecule that minimizes off-target toxicity," stated the director of antibody development at Creative Biolabs. "By aligning our rapid peptide generation protocols with omics-level validation, we ensure candidates are both structurally precise and functionally robust for demanding therapeutic applications." Technical FAQ: Ensuring Clinical Safety Through High-Density Profiling A recurring question among translational researchers is how to definitively map off-target liabilities prior to costly in vivo studies. The clinical solution requires exhaustive downstream validation. To answer this, extensive cross-reactivity and off-target screening are integrated into the workflow. Utilizing advanced protein microarrays containing thousands of distinct human proteins, this high-density analysis provides crucial predictive insights for early de-risking of candidate safety. This systematic profiling delivers three critical data points for AI-driven target analysis and human review: Off-Target Mitigation: Early identification of non-specific binding across the proteome, directly de-risking the clinical pipeline. Precise Epitope Mapping: Detailed mapping of binding sites to support functional mechanisms and solidify intellectual property claims. Species Cross-Reactivity: Verification of binding efficacy across relevant murine, primate, or other model organisms to streamline preclinical evaluation. Industry feedback underscores the efficacy of this end-to-end ecosystem. Laboratory partners consistently note that combining rapid, high-throughput discovery with rigorous proteomic profiling successfully rescues therapeutic programs previously stalled by unpredictable cross-reactivity or poor initial affinity. About Creative Biolabs Creative Biolabs is a CRO specializing in custom antibody discovery, engineering, and biomanufacturing. Leveraging state-of-the-art omics platforms and high-throughput automation, the company accelerates the trajectory of global pharmaceutical pipelines from conceptual target identification through definitive pre-clinical validation.
- March 12, 2026Medicine & Pharmaceuticals
Creative Biolabs Facilitates Drug Discovery for Next-Generation Probiotics: Focus on F. prausnitzii and A. muciniphila
The expansion specifically targets technical bottlenecks in the cultivation and functional validation of two high-value strains: Faecalibacterium prausnitzii and Akkermansia muciniphila . Advancing Clinical Translation of Key Commensal Bacteria Unlike traditional probiotics, Next-Generation Probiotics (NGPs) are characterized by their specific therapeutic potential for complex diseases. Creative Biolabs provides integrated solutions to transform these "star strains" into regulated medical products. Targeting Inflammation with Faecalibacterium prausnitzii : As a major producer of butyrate, this strain is a primary candidate for treating Crohn's disease and ulcerative colitis. Creative Biolabs' platform addresses the extreme oxygen sensitivity of F. prausnitzii , providing specialized anaerobic fermentation and bioactivity assays to ensure metabolic potency. Metabolic Regulation via Akkermansia muciniphila : Known for its role in maintaining the gut mucosal barrier, A. muciniphila is at the forefront of research into obesity, type 2 diabetes, and cancer immunotherapy (PD-1/PD-L1) enhancement. The company offers precise quantification and efficacy testing to support its pharmaceutical application. Expert Insight: From Commensal Microbes to Live Biotherapeutics "The industry is moving past general gut health toward targeted microbial drugs," stated a project lead at Creative Biolabs. "The difficulty lies in the transition from a laboratory isolate to a stable, scalable drug product. By optimizing the discovery pipeline for F. prausnitzii and A. muciniphila , we are helping our clients bridge the gap between microbiome signatures and clinical outcomes." Technical Framework: The LBP Development Pipeline Creative Biolabs utilizes a structured methodology to ensure that Live Biotherapeutic Products (LBPs) meet international regulatory expectations. Isolation & Identification : Utilizing metagenomic tools for strain-level precision. Safety Profiling : Screening for antibiotic resistance genes (ARGs) and virulence factors to ensure non-pathogenicity. Functional Assays : Evaluating immune-modulatory effects using co-culture systems and germ-free animal models. Process Development : Solving the stability challenges of live bacteria through proprietary lyophilization and encapsulation technologies. Technical Background: Solving NGP Challenges (FAQ) A frequent challenge in NGP development is the strict anaerobiosis required for many beneficial gut bacteria. Traditional manufacturing often fails to maintain high viability. Creative Biolabs addresses this by employing advanced anaerobic workstations and protective agents during the freeze-drying process. Additionally, for strains like A. muciniphila , the platform monitors the specific interaction between the bacteria and the host's mucus layer to ensure the intended therapeutic mechanism—restoring rather than degrading the gut barrier—is preserved. About Creative Biolabs is a leading biotech service provider with decades of experience in drug discovery. Its microbiome division is dedicated to providing high-quality research tools and contract services for the global biopharmaceutical industry, focusing on the therapeutic potential of the human microbiota.
- March 12, 2026Medicine & Pharmaceuticals
KT Medical Staffing Expands Concierge Nursing and Private Duty Nursing Services in Orange County
KT Medical Staffing, a leading provider of private nursing and concierge nursing services in Orange County, has expanded its in-home healthcare offerings to better serve families across Orange County. The expanded services are designed to support patients transitioning from hospital care to home, individuals managing chronic medical conditions, and seniors who require personalized medical attention in the comfort of their own homes. As healthcare systems continue to face increasing demand, many families are seeking reliable medical care outside of traditional clinical settings. KT Medical Staffing’s concierge nursing program provides licensed nurses who deliver professional medical oversight directly in patients’ homes, helping ensure continuity of care after hospital discharge and reducing the risk of complications that can lead to readmissions. The company’s private duty nurses assist patients recovering from surgery, managing long-term conditions, or requiring ongoing medical supervision. The company provides a comprehensive range of services including medication administration, chronic condition management, post-operative recovery support, and customized medical care designed around each patient’s individual needs. By providing dedicated in-home caregiver services, KT Medical Staffing helps families navigate complex health situations while improving patient safety and recovery outcomes. To meet the needs of families requiring continuous medical support, KT Medical Staffing also offers 24-hour private nursing services, ensuring patients receive around-the-clock monitoring and immediate response when medical concerns arise. This level of care is particularly valuable for seniors and individuals with complex health conditions who wish to remain safely at home while receiving professional medical attention. “Families today want high-quality medical care that allows their loved ones to recover and live comfortably at home,” said a spokesperson for KT Medical Staffing. “Our commitment is to provide personalized, professional nursing services that bring comfort, expertise, and peace of mind to patients and families during critical moments in their healthcare journey.” Based in Newport Beach, California, KT Medical Staffing provides concierge nursing, private duty nursing, chronic illness management, and senior in-home care services throughout Orange County. The company’s team of licensed nurses works closely with families and healthcare providers to create customized care plans that address each patient’s unique medical needs.
- March 11, 2026Medicine & Pharmaceuticals
Creative Biolabs Unveils Sophisticated 3D Co-Culture Platform to Strengthen Its Next-Gen Immunotherapies
As the landscape of oncology shifts toward more personalized treatments, the limitations of traditional 2D cell cultures in predicting clinical success have become a significant bottleneck. Addressing the critical need for higher physiological relevance, Creative Biolabs expands its 3D biology suite, integrating physiologically relevant tri-culture systems with high-precision functional evaluation platforms. Bridging the Gap: The Rise of Complex 3D Tri-Culture Models The cornerstone of this advancement is the development of a physiologically 3D tri-culture system involving stromal, endothelial, and immune cells. Unlike simplified monocultures, this platform recreates the structural complexity of the tumor microenvironment (TME) to govern tumor growth, angiogenesis, and immune evasion. "The integration of multiple cell types into a single 3D matrix is not just about complexity; it's about capturing the crosstalk that drives drug resistance," says a lead scientist at Creative Biolabs. "When we observe how stromal cells physically shield tumor clusters from immune infiltration, we gain data that a 2D assay simply cannot provide. This level of biological fidelity is what eventually reduces the 'attrition rate' in Phase I clinical trials." These models are specifically engineered to simulate biological barriers. By accounting for factors such as extracellular matrix (ECM) stiffness and nutrient gradients, the platform provides a robust environment for studying tumor growth and angiogenesis. Quantifying Efficacy via Immune Checkpoint and Killing Assays To maximize the utility of these 3D models, Creative Biolabs has synchronized them with advanced functional assays, essential for developing next-generation biologics like bispecific T-cell engagers (BiTEs). Immune Modulation Mapping: Through immune checkpoint screening services , researchers can monitor the dynamic interactions between PD-1/PD-L1 pathways within a 3D spatial context. Effector-Mediated Killing: The assessment of monocyte-mediated cytotoxicity serves as a critical endpoint. "By quantifying monocyte recruitment in a 3D volume, we can more accurately predict the antibody-dependent cellular phagocytosis (ADCP) activity of lead candidates," the technical lead added. Technical Analysis: Enhancing Drug Validation (FAQ Integration) The integration of these services addresses several critical industry requirements for 3D biology applications: How does the 3D model improve upon 2D assays? 3D spheroids facilitate realistic drug penetration gradients and cell-to-cell interactions, leading to more accurate IC50 values that align closer to in vivo results. What role do endothelial cells play in these models? They allow for the evaluation of anti-angiogenic effects and the study of immune cell extravasation within a controlled 3D environment. Can these platforms support large-molecule screening? Yes, the platforms are optimized for the development of complex biologics, ensuring that only candidates with high biological activity proceed to clinical trials. About Creative Biolabs With a particular emphasis on its 3D-based oncology models and functional immune assays, Creative Biolabs offers scalable, industry-standard solutions designed to accelerate IND-enabling studies and optimize drug development pipelines. Catering to a global clientele that spans both academic institutions and leading biopharmaceutical industries, the company provides the critical infrastructure needed to bridge the gap between early-stage discovery and clinical success.
- March 8, 2026Medicine & Pharmaceuticals
Spectrum Plasma Receives 2026 Global Recognition Award
Spectrum Plasma has been recognized with a 2026 Global Recognition Award for developing age- and sex-specific plasma collection that addresses one of healthcare’s most pressing challenges: the rising costs and prevalence of chronic diseases in aging populations. Photo Courtesy of Spectrum Plasma Operating as the only fully accredited blood bank worldwide to collect plasma exclusively from donors aged 18-25, Spectrum Plasma has implemented an innovation in a field where the infrastructure exists, but its differentiation represents a fundamental paradigm shift in regenerative medicine. Cellular aging and rejuvenation are regulated by blood plasma. Plasma is collected through a detoxifying dialysis-like process that is healthy to undergo frequently, and human studies have proven that by simply infusing plasma from young donors into the sex and blood-type matched aging, all the cells in their older bodies immediately respond by actively regenerating and restoring lost function, just as they did when young. “Spectrum Plasma has shown exceptional ability to translate regenerative medicine research into accessible treatments that benefit young donors and aging recipients, creating a sustainable model for community health that operates within existing infrastructure while delivering measurably superior outcomes,” noted Alex Sterling, spokesperson for Global Recognition Awards. About Company/Organization Name Spectrum Plasma, located in San Marcos, Texas, was founded by Tom Casey, a serial entrepreneur with decades of experience in medical technology and applied intelligence. The company is the only fully accredited blood bank in the world that collects plasma exclusively from donors aged 18 to 25. Its mission is to convert standard plasma collection into a precision regenerative medicine platform that operates within existing regulatory and distribution frameworks. The company has been recognized with a 2026 Global Recognition Award, earning the highest grade of 5 (exceptional/world-class) across six innovation categories: novelty and originality, market impact, technological advancement, addressing global challenges, adoption rate and user feedback, and disruption of existing paradigms. Spectrum Plasma’s prescribers’ ongoing patient interventions in 2026 continue to document neurological and systemic benefits of age- and sex-specific plasma therapeutics.
- March 7, 2026Medicine & Pharmaceuticals
Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
A growing number of families in Phoenix and across Arizona are seeking independent medical examinations through private autopsy services to find definitive answers following the loss of a loved one. This trend highlights a demand for deeper clarity and a second opinion when a cause of death is uncertain or not fully addressed by standard procedures. Private autopsies in Phoenix offer a pathway for families who are left with unresolved questions. While county medical examiner offices are often limited by jurisdiction or specific criteria for conducting autopsies, private services provide an alternative for those seeking a comprehensive investigation. For many, this independent examination is a crucial step in the grieving process, providing the transparency and peace of mind necessary for closure. These detailed medical insights can be invaluable. Beyond confirming a precise cause of death, a private autopsy can uncover hereditary conditions or genetic health risks that may have implications for surviving family members. The findings can also provide essential documentation and legal clarity for matters related to insurance claims, medical malpractice, or other legal proceedings. As families navigate the complexities of loss, private autopsy services in Phoenix, Arizona are becoming a vital resource. They empower individuals with thorough information, helping them find the answers they need to understand what happened and begin to heal. About Postmortem Pathology Serving Phoenix, Arizona, Postmortem Pathology specializes in independent autopsy services in Phoenix , helping families gain clarity through detailed, respectful, and confidential medical evaluations. Our team of board-certified pathologists is committed to delivering accurate answers and peace of mind during difficult times.
- February 27, 2026Medicine & Pharmaceuticals
Alfa Cytology Advances T-Cell Immunotherapy Research with In Vivo CAR-T Therapy Development Solutions
With the continuous development of immune cell therapy, CAR-T therapy has become an important direction of tumor immunotherapy research. To support early-stage exploration and evaluation of candidate immunotherapies, Alfa Cytology has established a technical support system covering molecular design, delivery strategy development, and in vivo validation models to help research teams improve the integrity and consistency of research data. Traditional CAR-T technology usually relies on in vitro cell engineering processes, including multiple steps such as T-cell isolation, genetic modification, in vitro expansion, and reinfusion, resulting in relatively complex workflows. In contrast, in vivo CAR-T therapy enables the in vivo generation of CAR-T cells by packaging CAR gene editing constructs into viral vectors or nanoparticle-based delivery systems and administering them through systemic delivery, providing an alternative research strategy for cellular immunotherapy development. Within its in vivo CAR-T therapy development service , Alfa Cytology supports the development and evaluation of viral vectors and non-viral delivery systems. Viral vectors include lentivirus, retrovirus, adeno-associated virus, and related technology platforms, which demonstrate efficient gene transduction capabilities. Non-viral systems, such as lipid nanoparticles and polymer-based nanocarriers, offer controllable gene expression strategies, providing diversified technical options to meet different research requirements. Relying on its T-cell immunotherapy development laboratory , Alfa Cytology has established a research workflow covering antigen screening, CAR structure design, and in vivo functional evaluation. Through its humanized immune model research platform, researchers can study CAR-T cell kinetics and tumor response characteristics, providing data support for immunotherapy research. In addition, the company’s alfaCAR-T™ (CAR-T cells with sustained therapeutic response) platform supports research into enhancing T-cell persistence and immune memory through optimized antigen recognition structures and signaling module design. Currently, in vivo CAR-T technology demonstrates research potential not only in hematological malignancy and solid tumor studies but also in investigations related to chronic infections and autoimmune disease-associated immune regulation, providing expanded research perspectives for next-generation immune engineering strategies. “In immunotherapy candidate strategy research, early experimental data provide important references for subsequent research directions,” said a spokesperson from Alfa Cytology. “By integrating in vivo CAR-T development technologies with sustained response optimization platforms, we aim to support research teams in conducting more systematic immunotherapy investigations.” About Alfa Cytology Alfa Cytology specializes in immunotherapy research support and disease model development and is committed to providing systematic early-stage research services for scientific research institutions, biotechnology companies, and related research organizations. In the field of T-cell immunotherapy research, the company focuses on CAR-T development support and functional research platform construction, providing experimental systems and technical services for research teams.
- February 27, 2026Medicine & Pharmaceuticals
Amerigo Scientific Expands Its Portfolio with Advanced Glycan Detection Kits for Glycomics Research
Amerigo Scientific recently announced its comprehensive range of glycan detection kits, designed to streamline the complex processes of glycan analysis and support groundbreaking research in glycomics, biopharmaceutical development, and disease biomarker discovery. These specialized kits address the growing demand for reliable, high-sensitivity tools to study glycans, whose critical biological roles make them a focal point of modern biomedical research. Glycans, carbohydrate chains linked to lipids or proteins via glycosylation, are key regulators of biological functions including protein folding, cell signaling, and immune response. Aberrant glycosylation is closely associated with cancer, autoimmune disorders, and infectious diseases, elevating the importance of precise glycan analysis in understanding disease mechanisms and identifying therapeutic targets. Amerigo Scientific's glycan detection kits deliver a streamlined solution for this vital research, integrating all necessary reagents for enzymatic digestion, labeling, and high-sensitivity detection via fluorescence, HPLC, or mass spectrometry—core techniques for unraveling glycan structure and function. Among these kits, Amerigo Scientific offers ready-to-use kits that are designed for N-linked or O-linked glycan analysis , two foundational areas of glycomics research, alongside specialized capabilities for sialic acid quantification, glycosaminoglycan profiling, and linkage-specific glycan detection. These kits eliminate the need for time-consuming reagent preparation, simplifying complex workflows and ensuring consistency across experiments—critical for both academic research and biopharmaceutical quality control. By simplifying glycan analysis workflows, Amerigo Scientific's glycan detection kits empower researchers to efficiently monitor glycosylation patterns, analyze glycan structures, and uncover the biological implications of these key molecules. The kits’ reliability and ease of use make them an invaluable resource for labs focused on n-glycan and o-glycan analysis, as well as those exploring sialic acid biology and glycan-based disease biomarkers. Amerigo Scientific remains committed to advancing life science research by providing high-quality, innovative tools that address unmet needs in emerging fields like glycomics. The glycan detection kit portfolio aligns with this mission, offering a robust solution for researchers seeking to decode the complex role of glycans in health and disease.
ALL NEWS
- Jennings Real Estate Secures Industrial Warehouse Lease Springfield MA for Regional Distribution Center at 100 Brookdale Drive
- LEAD Development Showcases Jubail Island’s Integrated Water System Amid UAE Rainfall
- Brian Ferdinand Expands Thought Leadership Through Forbes Business Development Council
- SMS Activate Enhances Virtual Number Infrastructure to Support Secure Online Verification
- The AI Marketing Team That Never Sleeps, Never Bills, and Never Misses: JustAd Launches an AI That Runs an Entire Advertising Operation From a Single Prompt
- AI, Data and Community Insight Power a New Approach to Disaster Risk in Southeast Asia
- Tricycle Film Festival Expands Internationally with Pure Land Foundation Partnership
- Australian FBT Compliance Guide & 2026 Year End Checklist Released
- New Book Jimmy & I by Maxmillian Kunitz Delivers a Powerful Story of Transformation, Loss, and Redemption
- Hurley Write Announces PROS Communication Diagnostic for Workplace Communication Issues
- Kim Markwat Builds Light Tree Technology into a Global Innovation Partner for Beauty and Health Brands
- Ivor Alex Drives Global Recruitment and Leadership Innovation at Norman Alex
- RE/MAX Group Expands Florida CRE Advisory
- mikeipin Launches Magic Books for Bilingual Storytelling
- Cajabra Announces Revenue Architecture Framework for Accounting Firms
- MEDLIFE’s Field Education model beyond traditional volunteering
- The Village App Announces New Way to Build Local Connections
- Precision Medicine Software Market Size to Reach USD 3.49 Billion by 2031 Driven by AI Integration, Genomics Expansion, and Cloud Adoption
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS